TITLE

THROMBOGENICS SIGNS DEAL WITH MSD FOR MICROPLASIN SUPPLY

PUB. DATE
November 2010
SOURCE
Worldwide Biotech;Nov2010, Vol. 22 Issue 11, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article focuses on the supply agreement signed between ThromboGenics NV and MSD Biologics (UK) Ltd. for the production of microplasmin. The deal is expected by ThromboGenics to address its long-term commercial needs for bulk drug substance of this therapeutic agent. Particular focus is given to the outcome of microplasmin clinical trials. There is a plan by MSD Biologics to produce microplasmin at its facility in Billingham, England. Patrick De Haes of ThromboGenics notes that the deal is part of their preparations to commecialize microplasmin.
ACCESSION #
54993765

 

Related Articles

  • ThromboGenics Stock Up on Microplasmin Data.  // Bioworld Week;4/26/2010, Vol. 18 Issue 17, p4 

    The article reports that ThromboGenics NV's traded shares have reached an all-time high during its early trading on April 20, 2010 in view of the success of the Phase III trials of its lead drug microplasmin for the treatment of symptomatic focal vitreomacular adhesion (VMA).

  • ThromboGenics Extends Runway with $103.2M Raise. Powers, Marie // BioWorld Today;3/30/2012, Vol. 23 Issue 62, p1 

    The article reports on the 77.8 million euros in funding raised by ThromboGenics NV via a private placement deal with both domestic and international investors. The cash position of Belgium-based ThromboGenics has been boosted to 230 million euros as a result of the deal. ThromboGenics Chief...

  • FDA Insists on Priority Review For VMA Drug Ocraplasmin. Sheridan, Cormac // BioWorld Today;2/8/2012, Vol. 23 Issue 17, p3 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to review the Biologics License Application (BLA) of ThromboGenics NV for its symptomatic vitreomacular adhesion (VMA) drug ocraplasmin. According to Patrik De Haes, chief executive officer (CEO) of ThromboGenics,...

  • THROMBOGENICS STARTS PHASE IIA OF MICROPLASMIN FOR STROKE.  // Worldwide Biotech;Nov2006, Vol. 18 Issue 11, p3 

    The article reports on a phase IIa trial initiated by ThromboGenics NV to evaluate microplasmin for the intra-arterial treatment of stroke. The study will enroll patients with acute vertebro-basilar artery occlusion. The purpose is to obtain initial safety information in the acute stroke patient...

  • ThromboGenics Extends Runway with $103.2M Raise. Powers, Marie // BioWorld International;4/4/2012, Vol. 17 Issue 14, p1 

    The article reports on the 77.8 million euros in funding raised by ThromboGenics NV via a private placement deal with both domestic and international investors. The cash position of Belgium-based ThromboGenics has been boosted to 230 million euros as a result of the deal. ThromboGenics Chief...

  • Clinic Roundup.  // BioWorld Today;8/23/2011, Vol. 22 Issue 163, p5 

    This section offers news briefs on drug clinical trials, which include the adult mesenchymal precursor cell product of Mesoblast Ltd. and the ocriplasmin trial for focal vitreomacular adhesion developed by ThromboGenics NV.

  • ThromboGenics Signs Potential $494M Ex-U.S. Ocriplasmin Deal. Moran, Nuala // BioWorld Today;3/19/2012, Vol. 23 Issue 43, p1 

    The article reports on ThromboGenics NV initially getting paid 75 million euros by Alcon Inc. The royalty given is for the exclusive rights of ocriplasmin in the U.S. ThromboGenics will receive a further amount of 90 million euros for the launching and approval of the said recombinant form of...

  • ThromboGenics Stock Climbs on Microplasmin Phase III Data. Sheridan, Cormac // BioWorld Today;4/21/2010, Vol. 21 Issue 76, p1 

    The article reports that shares in ThromboGenics NV reached its highest price at 18.80 euros following news that its lead drug candidate microplasmin posted good results in the first of two Phase III trials for treating symptomatic focal vitreomacular adhesion (VMA). The trial, which involved...

  • Financings Roundup.  // BioWorld Today;9/21/2007, Vol. 18 Issue 184, p6 

    The article reports that ThromboGenics NV strengthened its cash position by &euro5.1 million through the exercise of 1.1 million pledges. It is stated that the company's number of outstanding shares increased to 25.5 million. ThromboGenics has various programs in the clinic which is in Phase II...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics